There were 1,824 press releases posted in the last 24 hours and 442,411 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image